Plasmid manufacturing services are provided for various applications such as preclinical research studies, clinical trials, and commercial manufacturing. Pure, high-quality plasmid DNA is critical for a successful transfection. Research-grade plasmid can be used to generate viral particles such as AAV, adenovirus, or lentivirus for in vitro or in vivo research applications. However, research-grade plasmid DNA cannot be used to generate viral vectors intended for human use and cannot be directly administered to humans.
The report analyzes and forecasts the Viral vectors and plasmid DNA manufacturing market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of Viral vectors and plasmid DNA manufacturing, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Viral vectors and plasmid DNA manufacturing companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Viral vectors and plasmid DNA manufacturing upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of Viral vectors and plasmid DNA manufacturing and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global Viral vectors and plasmid DNA manufacturing market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the Viral vectors and plasmid DNA manufacturing market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of Viral vectors and plasmid DNA manufacturing market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Some of the major factors expected to drive the growth of the target market are rapid technological advancements in healthcare sector, increasing government expenditure on development of healthcare R&D infrastructure, coupled with increasing use of viral and non-viral vectors for development of innovative medicines. In addition, rapid growth in therapeutic development from clinical evaluation, coupled with manufacturers approach towards development of optimized large-scale production, harvest, and purification related to product purity are some other factors expected to further support the growth of the target market. The global viral vector & plasmid DNA manufacturing market is expected to grow at CAGR 25.3% during the forecast period.
However, high manufacturing cost and stringent government regulation related to product approval are some major factors expected to hamper the growth of the target market. In addition, lack of required infrastructure for R&D activities in developing countries is expected to limit the growth of the market to a certain extent.
The viral vector & plasmid DNA manufacturing market is fragmented into large number of players in both domestic and international markets. Key players approach towards shifting their manufacturing units to developing countries in order to increase their presence is further accelerating the market growth. Developing regulatory scenario in emerging economies such as China and India is expected to support the market growth. Cobra Biologics Limited, Aldevron, Delphi Genetics, VGXI, Inc., PlasmidFactory GmbH & Co. KG, LakePharma, Inc., Akron Biotech, and Waisman Biomanufacturing are some of the major players operating in the market. Continuous business activities by players through merger & acquisition activities in order to increase their profit share and dominance in the global market will create new opportunities for players operating in the market.
Market Segmentation
Global Viral Vector & Plasmid DNA Manufacturing Market, by Type
Global Viral Vector & Plasmid DNA Manufacturing Market, by Application
Global Viral Vector & Plasmid DNA Manufacturing Market, by Disease
Global Viral Vector & Plasmid DNA Manufacturing Market, by End Use
Global Viral Vector & Plasmid DNA Manufacturing Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
CHAPTER 1. INDUSTRY OVERVIEW
1.1. Definition and Scope
1.1.1. Definition of Viral Vector & Plasmid DNA Manufacturing
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Viral Vector & Plasmid DNA Manufacturing Market By Type
1.2.2.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Type (2015-2026)
1.2.2.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Type in 2017
1.2.2.3. Lentivirus
1.2.2.4. Adenovirus
1.2.2.5. Plasmid DNA
1.2.2.6. Adeno-Associated Virus
1.2.2.7. Others
1.2.3. Viral Vector & Plasmid DNA Manufacturing Market By Application
1.2.3.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Application (2015-2026)
1.2.3.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Application in 2017
1.2.3.3. Gene Therapy
1.2.3.4. Vaccinology
1.2.4. Viral Vector & Plasmid DNA Manufacturing Market By Disease
1.2.4.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By Disease (2015-2026)
1.2.4.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By Disease in 2017
1.2.4.3. Infectious Disease
1.2.4.4. Genetic Disorders
1.2.4.5. Cancer
1.2.4.6. Others
1.2.5. Viral Vector & Plasmid DNA Manufacturing Market By End Use
1.2.5.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison By End Use (2015-2026)
1.2.5.2. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue Share By End Use in 2017
1.2.5.3. Research Institutes
1.2.5.4. Biotech Companies
1.2.5.5. Others
1.2.6. Viral Vector & Plasmid DNA Manufacturing Market by Geography
1.2.6.1. Global Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.6.2. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.3. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.4. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.5. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
1.2.6.6. Middle East and Africa (MEA) Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate (2015-2026)
CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS
2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porter’s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players
CHAPTER 3. MANUFACTURING PLANTS ANALYSIS
3.1. Capacity and Commercial Production Date of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.3. R&D Status and Technology Source of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Viral Vector & Plasmid DNA Manufacturing Major Manufacturers in 2017
CHAPTER 4. Viral Vector & Plasmid DNA Manufacturing Market By Type
4.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Type
4.2. Lentivirus
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Adenovirus
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Plasmid DNA
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Adeno-Associated Virus
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Others
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 5. Viral Vector & Plasmid DNA Manufacturing Market By Application
5.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Application
5.2. Gene Therapy
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Vaccinology
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.4. Others
5.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 6. Viral Vector & Plasmid DNA Manufacturing Market By Disease
6.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By Disease
6.2. Infectious Disease
6.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.3. Genetic Disorders
6.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.4. Cancer
6.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
6.5. Others
6.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 7. Viral Vector & Plasmid DNA Manufacturing Market By End Use
7.1. Global Viral Vector & Plasmid DNA Manufacturing Revenue By End Use
7.2. Research Institutes
7.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.3. Biotech Companies
7.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
7.4. Others
7.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
CHAPTER 8. North America Viral Vector & Plasmid DNA Manufacturing Market By Country
8.1. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. North America Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
8.3. U.S.
8.3.1. U.S. Viral Vector & Plasmid DNA Manufacturing Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.4. Canada
8.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
8.5. Mexico
8.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
CHAPTER 9. Europe Viral Vector & Plasmid DNA Manufacturing Market By Country
9.1. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Europe Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
9.3. UK
9.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.4. Germany
9.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.5. France
9.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.6. Spain
9.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
9.7. Rest of Europe
9.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
9.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
CHAPTER 10. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market By Country
10.1. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
10.3. China
10.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.4. Japan
10.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.5. India
10.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.6. Australia
10.6.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.6.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.7. South Korea
10.7.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.7.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
10.8. Rest of Asia-Pacific
10.8.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
10.8.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
CHAPTER 11. Latin America Viral Vector & Plasmid DNA Manufacturing Market By Country
11.1. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Latin America Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
11.3. Brazil
11.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.4. Argentina
11.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
11.5. Rest of Latin America
11.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
CHAPTER 12. Middle East Viral Vector & Plasmid DNA Manufacturing Market By Country
12.1. Middle East Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
12.2. Middle East Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
12.3. Saudi Arabia
12.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.4. UAE
12.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
12.5. Rest of Middle East
12.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
12.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
CHAPTER 13. Africa Viral Vector & Plasmid DNA Manufacturing Market By Country
13.1. Africa Viral Vector & Plasmid DNA Manufacturing Market Revenue and Growth Rate, 2015 - 2026 ($Million)
13.2. Africa Viral Vector & Plasmid DNA Manufacturing Market Revenue Share Comparison, 2015 & 2026 (%)
13.3. South Africa
13.3.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.3.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
13.4. Egypt
13.4.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.4.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
13.5. Rest of Africa
13.5.1. Market Revenue and Forecast By Type, 2015 - 2026 ($Million)
13.5.2. Market Revenue and Forecast By End-user, 2015 - 2026 ($Million)
CHAPTER 14. COMPANY PROFILE
14.1. CobraBiologics
14.1.1. Company Snapshot
14.1.2. Overview
14.1.3. Financial Overview
14.1.4. Product Portfolio
14.1.5. Key Developments
14.1.6. Strategies
14.2. Novasep
14.2.1. Company Snapshot
14.2.2. Overview
14.2.3. Financial Overview
14.2.4. Product Portfolio
14.2.5. Key Developments
14.2.6. Strategies
14.3. Spark Therapeutics, Inc.
14.3.1. Company Snapshot
14.3.2. Overview
14.3.3. Financial Overview
14.3.4. Product Portfolio
14.3.5. Key Developments
14.3.6. Strategies
14.4. FUJIFILM Diosynth Ltd
14.4.1. Company Snapshot
14.4.2. Overview
14.4.3. Financial Overview
14.4.4. Product Portfolio
14.4.5. Key Developments
14.4.6. Strategies
14.5. Cell and Gene Therapy Catapult
14.5.1. Company Snapshot
14.5.2. Overview
14.5.3. Financial Overview
14.5.4. Product Portfolio
14.5.5. Key Developments
14.5.6. Strategies
14.6. Kaneka Eurogentec, Inc.
14.6.1. Company Snapshot
14.6.2. Overview
14.6.3. Financial Overview
14.6.4. Product Portfolio
14.6.5. Key Developments
14.6.6. Strategies
14.7. Merck KGaA
14.7.1. Company Snapshot
14.7.2. Overview
14.7.3. Financial Overview
14.7.4. Product Portfolio
14.7.5. Key Developments
14.7.6. Strategies
14.8. Lonza
14.8.1. Company Snapshot
14.8.2. Overview
14.8.3. Financial Overview
14.8.4. Product Portfolio
14.8.5. Key Developments
14.8.6. Strategies
14.9. UniQure N.V.
14.9.1. Company Snapshot
14.9.2. Overview
14.9.3. Financial Overview
14.9.4. Product Portfolio
14.9.5. Key Developments
14.9.6. Strategies
14.10. Others
14.10.1. Company Snapshot
14.10.2. Overview
14.10.3. Financial Overview
14.10.4. Product Portfolio
14.10.5. Key Developments
14.10.6. Strategies
CHAPTER 15. RESEARCH APPROACH
15.1. Research Methodology
15.1.1. Initial Data Search
15.1.2. Secondary Research
15.1.3. Primary Research
15.2. Assumptions and Scope